VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Friday, January 2, 2026
Stock Comparison
Brown-Forman Corporation vs Novartis AG
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Brown-Forman Corporation
BF.B · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Brown-Forman Corporation's moat claims, evidence, and risks.
View BF.B analysisNovartis AG
NOVN · SIX Swiss Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Novartis AG's moat claims, evidence, and risks.
View NOVN analysisComparison highlights
- Moat score gap: Brown-Forman Corporation leads (72 / 100 vs 65 / 100 for Novartis AG).
- Segment focus: Brown-Forman Corporation has 5 segments (71.1% in Whiskey); Novartis AG has 5 segments (29.3% in Oncology).
- Moat breadth: Brown-Forman Corporation has 4 moat types across 2 domains; Novartis AG has 4 across 3.
Primary market context
Brown-Forman Corporation
Whiskey
Premium-and-above whiskey spirits (American whiskey and import whiskies)
Global
Consumer (off-premise and on-premise via distributors/retailers)
Brand owner / distiller / marketer
71.1%
Novartis AG
Oncology
Oncology and hematology branded medicines (including targeted therapies and radioligand therapy)
Global
Oncologists and hospitals; reimbursed by payers; hospital and specialty pharmacy channels
Originator developer, manufacturer, and marketer of oncology therapies
29.3%
Side-by-side metrics
Moat coverage
Shared moat types
Brown-Forman Corporation strengths
Novartis AG strengths
Segment mix
Brown-Forman Corporation segments
Full profile >Whiskey
Oligopoly
Ready-to-Drink (RTD/RTP)
Competitive
Tequila
Oligopoly
Rest of Portfolio (Other Branded Spirits)
Competitive
Non-branded and Bulk
Competitive
Novartis AG segments
Full profile >Cardiovascular, Renal and Metabolic
Oligopoly
Immunology
Oligopoly
Neuroscience
Oligopoly
Oncology
Oligopoly
Established Brands
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.